Format

Send to

Choose Destination
Semin Liver Dis. 2015 Feb;35(1):63-74. doi: 10.1055/s-0034-1397350. Epub 2015 Jan 29.

Noncoding RNA as therapeutic targets for hepatocellular carcinoma.

Author information

1
Department of Cancer Biology, Mayo Clinic, Jacksonville, Florida.
2
Departments of Transplantation and Cancer Biology, Mayo Clinic, Jacksonville, Florida.

Abstract

Recent studies have suggested that noncoding RNAs (ncRNAs) contribute to the pathogenesis and progression of hepatocellular carcinoma (HCC). These RNA genes may be involved in various pathobiological processes such as cell proliferation, apoptosis, angiogenesis, invasion, and metastasis. Aberrant expression of ncRNA resulting from deregulated epigenetic, transcriptional, or posttranscriptional activity has been described in several studies. ncRNAs are comprised of a highly diverse group of transcripts that include microRNAs (miRNAs) and long noncoding RNAs (lncRNAs) as well as several other types of RNA genes. Understanding the molecular mechanisms by which ncRNA contribute to hepatocarcinogenesis may enable the design of ncRNA-based therapeutics for HCC. In this review, the authors provide a perspective on therapeutic applications based on the emerging evidence of a contributory role of miRNAs and lncRNAs to the pathogenesis and progression of HCC. In addition, ncRNAs that are deregulated in expression in HCC may have utility as potential prognostic or diagnostic markers.

PMID:
25632936
PMCID:
PMC4427038
DOI:
10.1055/s-0034-1397350
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Georg Thieme Verlag Stuttgart, New York Icon for PubMed Central
Loading ...
Support Center